中国实用医刊
中國實用醫刊
중국실용의간
Chinese Journal of Practical Medicine
2015年
24期
52-53
,共2页
围术期%输血%恶性肿瘤%影响
圍術期%輸血%噁性腫瘤%影響
위술기%수혈%악성종류%영향
Perioperative%Transfusion%Malignant tumor%Effects
目的 探究围术期输血对恶性肿瘤患者的影响.方法 选取安阳市肿瘤医院2012年6月至2014年9月收治的156例恶性肿瘤患者为研究对象,从输血方案出发将患者分为三组:A组29例行去白细胞血液输注,涵盖血浆、红细胞及冷沉淀、血小板,B组17例行自体输血,C组110例未做输血处理.观察三组免疫功能变化情况,并分析输血后不良反应发生情况及3、5年内转移复发、生存状况.结果 凝血功能变化:A组lgG、IgA[(9.14±0.35) g/Lvs (12.44±0.34) g/L,(2.10±0.31) g/L vs(2.67±0.30)g/L]均低于B组,差异有统计学意义(P＜0.05).A组不良反应发生率、3年内转移复发率、5年内生存率分别为6.89％、31.03％、48.27％,B组分别为48.27％、48.27％、70.58％,C组分别为0、23.63％、66.36％,B、C组与A组比较差异有统计学意义(P＜0.05).结论 针对恶性肿瘤患者而言,临床上严格把控输血指征,尽可能地采用血液替代品或自体输血,对提升输血质量、改善患者预后具有积极的应用意义,临床上需引起重视.
目的 探究圍術期輸血對噁性腫瘤患者的影響.方法 選取安暘市腫瘤醫院2012年6月至2014年9月收治的156例噁性腫瘤患者為研究對象,從輸血方案齣髮將患者分為三組:A組29例行去白細胞血液輸註,涵蓋血漿、紅細胞及冷沉澱、血小闆,B組17例行自體輸血,C組110例未做輸血處理.觀察三組免疫功能變化情況,併分析輸血後不良反應髮生情況及3、5年內轉移複髮、生存狀況.結果 凝血功能變化:A組lgG、IgA[(9.14±0.35) g/Lvs (12.44±0.34) g/L,(2.10±0.31) g/L vs(2.67±0.30)g/L]均低于B組,差異有統計學意義(P＜0.05).A組不良反應髮生率、3年內轉移複髮率、5年內生存率分彆為6.89％、31.03％、48.27％,B組分彆為48.27％、48.27％、70.58％,C組分彆為0、23.63％、66.36％,B、C組與A組比較差異有統計學意義(P＜0.05).結論 針對噁性腫瘤患者而言,臨床上嚴格把控輸血指徵,儘可能地採用血液替代品或自體輸血,對提升輸血質量、改善患者預後具有積極的應用意義,臨床上需引起重視.
목적 탐구위술기수혈대악성종류환자적영향.방법 선취안양시종류의원2012년6월지2014년9월수치적156례악성종류환자위연구대상,종수혈방안출발장환자분위삼조:A조29례행거백세포혈액수주,함개혈장、홍세포급랭침정、혈소판,B조17례행자체수혈,C조110례미주수혈처리.관찰삼조면역공능변화정황,병분석수혈후불량반응발생정황급3、5년내전이복발、생존상황.결과 응혈공능변화:A조lgG、IgA[(9.14±0.35) g/Lvs (12.44±0.34) g/L,(2.10±0.31) g/L vs(2.67±0.30)g/L]균저우B조,차이유통계학의의(P＜0.05).A조불량반응발생솔、3년내전이복발솔、5년내생존솔분별위6.89％、31.03％、48.27％,B조분별위48.27％、48.27％、70.58％,C조분별위0、23.63％、66.36％,B、C조여A조비교차이유통계학의의(P＜0.05).결론 침대악성종류환자이언,림상상엄격파공수혈지정,진가능지채용혈액체대품혹자체수혈,대제승수혈질량、개선환자예후구유적겁적응용의의,림상상수인기중시.
Objective To investigate the effects of perioperative blood transfusion on patients with malignant tumor.Methods One hundred and fifty-six patients with malignant tumor from June 2012 to September 2014 were divided into three groups starting from the blood transfusion solution.Twenty-nine patients in group A were given leukocyte blood transfusion, covering plasma, red blood cells and cryoprecipitate, platelets;Seventeen patients in group B were given autologous blood transfusion;One hundred and ten patients in group C were not given transfusion, the changes of immune function in three groups were observed, then the occurrence of adverse reactions after blood transfusion and the metastasis and recurrence, survival status in 3, 5 years were analyzed.Results Coagulationchanges: lgG, IgA in group A were (9.14±0.35) g/L, (2.10 ±0.31) g/L respectively;lgG, IgA in group B were (12.44 ±0.34) g/L, (2.67 ± 0.30) g/L respectively, the former was lower than the latter, the differences were significant (P ＜ 0.05).The incidence of adverse reactions, the rate of metastasis and recurrence in 3 years, the survival rate in 5 years: group A were 6.89％, 31.03％ and 48.27％ respectively;group B were 48.27％, 48.27％ and 70.58％ respectively;group C were 0, 23.63％ and 66.36％ respectively, compared group B, C with group A, the differences were significant (P ＜ 0.05).Conclusions As for the patients with malignant tumor, strictly control the clinical blood transfusion syndrome, and use blood substitutes or autologous blood transfusion as far as possible, there is positive significance to enhancing the quality of blood transfusion and improving the prognosis of patients, and we should pay much attention to it in clinics.
